Cargando…

Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor

Duchenne muscular dystrophy (DMD) is caused by lack of functional dystrophin and results in progressive myofiber damage and degeneration. In addition, impaired muscle regeneration and fibrosis contribute to the progressive pathology of DMD. Importantly, transforming growth factor-β (TGF-β) is implic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kemaladewi, Dwi U, Pasteuning, Svitlana, van der Meulen, Joke W, van Heiningen, Sandra H, van Ommen, Gert-Jan, ten Dijke, Peter, Aartsma-Rus, Annemieke, ‘t Hoen, Peter AC, Hoogaars, Willem M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011125/ https://www.ncbi.nlm.nih.gov/pubmed/24691207 http://dx.doi.org/10.1038/mtna.2014.7

Ejemplares similares

Novel Ex Vivo Culture Method for the Study of Dupuytren's Disease: Effects of TGFβ Type 1 Receptor Modulation by Antisense Oligonucleotides
por: Karkampouna, Sofia, et al.
Publicado: (2014)

Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva
por: Shi, SongTing, et al.
Publicado: (2013)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP)
por: Yılmaz-Eliş, A Seda, et al.
Publicado: (2013)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Targeting TGFβ Signaling to Address Fibrosis Using Antisense Oligonucleotides
por: March, James T., et al.
Publicado: (2018)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
por: Evers, Melvin M., et al.
Publicado: (2011)

Regulation of endothelial cell plasticity by TGF-β
por: van Meeteren, Laurens A., et al.
Publicado: (2011)

Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
por: Jirka, Silvana M.G., et al.
Publicado: (2018)

TGFβ Signaling and Cardiovascular Diseases
por: Pardali, Evangelia, et al.
Publicado: (2012)

TGF-β in progression of liver disease
por: Dooley, Steven, et al.
Publicado: (2011)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration
por: Pasteuning-Vuhman, Svitlana, et al.
Publicado: (2017)

Age-dependent alteration of TGF-β signalling in osteoarthritis
por: van der Kraan, Peter M., et al.
Publicado: (2011)

TGF‐β signaling in liver metastasis
por: Marvin, Dieuwke L, et al.
Publicado: (2020)

Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
por: van Putten, Maaike, et al.
Publicado: (2019)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Opposing USP19 splice variants in TGF-β signaling and TGF-β-induced epithelial–mesenchymal transition of breast cancer cells
por: Zhang, Jing, et al.
Publicado: (2023)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Editorial: TGF-β and BMP signaling in cancer
por: Yan, Xiaohua, et al.
Publicado: (2022)

Targeting TGFβ signal transduction for cancer therapy
por: Liu, Sijia, et al.
Publicado: (2021)

Reconditioning the Neurogenic Niche of Adult Non-human Primates by Antisense Oligonucleotide-Mediated Attenuation of TGFβ Signaling
por: Peters, Sebastian, et al.
Publicado: (2021)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

TGFβ-mediated expression of TGFβ-activating integrins in SSc monocytes: disturbed activation of latent TGFβ?
por: van Caam, A., et al.
Publicado: (2020)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
por: Goossens, Remko, et al.
Publicado: (2023)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer
por: Suriyamurthy, Sudha, et al.
Publicado: (2019)

TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
por: Hao, Yang, et al.
Publicado: (2019)

TGF-β Signaling in Breast Cancer Cell Invasion and Bone Metastasis
por: Drabsch, Yvette, et al.
Publicado: (2011)

Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2023)

Key role for ubiquitin protein modification in TGFβ signal transduction
por: De Boeck, Miriam, et al.
Publicado: (2012)

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
por: Huynh, Linh Khanh, et al.
Publicado: (2019)

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Assessment of active TGFβ with a bioassay
por: Laarhoven, Annemieke, et al.
Publicado: (2011)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
por: van den Bulk, Jitske, et al.
Publicado: (2021)

TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
por: Pardali, Evangelia, et al.
Publicado: (2017)

Role of glycosylation in TGF-β signaling and epithelial-to-mesenchymal transition in cancer
por: Zhang, Jing, et al.
Publicado: (2020)

TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering
por: Ma, Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9c1stbh2gru91v7673cr2nh31b